Archive · 8 Nov 2025
SMS Pharmaceuticals Reports 76% Profit Rise in Q2
SMS Pharmaceuticals, a company that makes medicines, had a really great financial quarter.
Their profit went up by a huge 76% compared to last year, reaching ₹25.14 crore.
They also sold more of their medicines, with sales going up by over 23% to ₹242.4 crore.
This good performance is because people are buying more of their products across different areas.
The company also managed its costs well, leading to a significant increase in their earnings before interest, taxes, depreciation, and amortization (EBITDA).
This strong financial result shows the company is doing well.
SMS Pharmaceuticals reported a 76% year-on-year increase in net profit to ₹25.14 crore for Q2 FY26.
Revenue from operations rose by 23.2% to ₹242.4 crore in Q2 FY26.
EBITDA for the quarter increased by 51.8% to ₹48.34 crore.
The growth was driven by healthy demand across key segments.
The company's operational performance contributed to the rise in profits.
- Who
- SMS Pharmaceuticals Ltd
- What
- Reported a 76% year-on-year increase in net profit to ₹25.14 crore and a 23.2% rise in revenue from operations to ₹242.4 crore for Q2 FY26.
- When
- Quarter ended September 30, 2025 (Q2 FY26).
- Where
- Operations span across India with healthy demand across key segments.
- Why
- Growth driven by strong operational performance and healthy demand across key business segments.
Previous Performance
Current Performance
Net Profit
Previous Performance
Q2 FY25 net profit was ₹14.28 crore.
Current Performance
Q2 FY26 net profit increased by 76% to ₹25.14 crore.
Revenue from Operations
Previous Performance
Q2 FY25 revenue was ₹196.7 crore.
Current Performance
Q2 FY26 revenue increased by 23.2% to ₹242.4 crore.
EBITDA
Previous Performance
Q2 FY25 EBITDA was ₹31.85 crore.
Current Performance
Q2 FY26 EBITDA grew by 51.8% to ₹48.34 crore.
- Company Name
- SMS Pharmaceuticals Ltd
- Reporting Period
- Q2 FY26 (Quarter ended September 30, 2025)
- Net Profit
- ₹25.14 crore (up 76% YoY)
- Revenue from Operations
- ₹242.4 crore (up 23.2% YoY)
- EBITDA
- ₹48.34 crore (up 51.8% YoY)
Sources
Sun Pharma investors await clarity on US tariff after weak Q2
Divi's Labs Q2 profit rises 35% YoY to Rs 689 crore; shares slip nearly 4%
Zydus PAT rises 38% on strong India, US growth
Solara Active Pharma shares down 20% in 2025 so far; analysts divided on outlook
Torrent Pharma Q2 profit rises 30% YoY, revenue up 14% on strong India, US growth
Torrent Pharma report 30.5% rise in net profit for Q2 FY26
